Agilent Technologies, Inc. (A)
Health Care · Life Sciences Tools & Services · US stock · S&P 500 component
$172.97
▼ -2.58 (1.47%)
Fair valueOvervalued
$123 −29.2% to fair value
$61fair band $86–$159$184
Day's range
$172.16 – $177.47
52-week range
$107.98 – $177.47
About Agilent Technologies, Inc.
Agilent Technologies provides instruments, software, consumables and services for laboratories. Its products include liquid and gas chromatography systems, mass spectrometers, genomic and cell analysis tools, and diagnostic tests and reagents. Customers work in pharmaceuticals, diagnostics, chemicals, food testing, environmental testing and academic research. The company is organised into life sciences and applied markets, diagnostics and genomics, and a laboratory services business.
Agilent earns revenue from new instruments and from the recurring consumables, service contracts and software that laboratories use with them. Over the last twelve months it was $7.4 billion, growing at 0.5% a year across the last three years. The operating margin is 22.2%, and the business earns a profit of 15% on the capital invested in it. It carries net debt of 1.3 times EBITDA. A dividend is paid, with a yield of 0.6%. On the site's X-Ray Score it receives 42 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $107.98 – $177.47Volume 2,900,100Daily, split-adjusted
Vitals
Market cap$49.0B
52-week range$107.98 – $177.47
Volume (last day)2,900,100
P/E (TTM)34.1
EBIT / EV yield3.2%
Free-cash-flow yield2.6%
Dividend yield0.6%
Revenue (TTM)$7.4B
Net income (TTM)$1.4B
Operating margin22.2%
Return on capital14.6%
Debt incl. leases$4.1B
Cash & securities$1.8B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$123model spread $117 – $127
Overvalued
−29.2% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $173
Undervalued < $86Fair $86 – $159Overvalued > $159
10-year DCF (market-scaled)
$112
Peer multiples
$133
Earnings power floor (not blended)
$48
Fundamentals-adjusted multiple
$122
Growth the price implies
20.0%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
29/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield3.2%
Free-cash-flow yield2.6%
Fair value vs price0.7×
Growth
Weak
35/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)0.5%
EPS growth (3y)3.0%
Growth consistency80%
Profitability
Fair
52/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital14.6%
Operating margin22.2%
Gross profitability28.4%
Financial health
Fair
50/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA1.3×
Interest cover15.5×
Dividends
Fair
50/100
Dividend is typical for its sector.
See the numbers →
Dividend yield0.6%
Dividends vs free cash flow23%
Dividend growth4.1%
Quarterly results: last 6 quarters
+6.0%
Apr '25
+10.1%
Jul '25
+9.4%
Oct '25
+7.0%
Jan '26
+10.0%
Apr '26
+8.1%
Jul '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.9B, diluted EPS $1.28.
Compare with peers
MTD Mettler Toledo Interna...50 IQV Iqvia Holdings Inc.42 TECH BIO-TECHNE Corp40 ILMN Illumina, Inc.39Other Life Sciences Tools & Services companies by X-Ray Score.
Fundamentals checklist
● 3 Good · ● 8 Average · ● 5 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldBad
Risk models
Altman Z''Average
Piotroski F-ScoreBad
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Average
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioGood
Net debt / EBITDAGood
Interest coverAverage
Valuation
Fair value vs priceAverage
EBIT / EV yieldAverage
Profitability
Return on invested capitalAverage
Operating marginGood
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 41/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $6.3B | $6.8B | $6.8B | $6.5B | $6.9B |
| Operating income | $1.3B | $1.6B | $1.4B | $1.5B | $1.5B |
| Net income | $1.2B | $1.3B | $1.2B | $1.3B | $1.3B |
| Operating cash flow | $1.5B | $1.3B | $1.8B | $1.8B | $1.6B |
| Operating margin | 21.3% | 23.6% | 19.8% | 22.9% | 21.3% |
| Free cash flow | $1.3B | $1.0B | $1.5B | $1.4B | $1.2B |
| Diluted EPS | $3.94 | $4.18 | $4.19 | $4.43 | $4.57 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 4 neutral · 0 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 171.4 | Bullish |
| EMA 10 | 171.7 | Bullish |
| SMA 20 | 170.4 | Bullish |
| EMA 20 | 168.5 | Bullish |
| SMA 50 | 158.7 | Bullish |
| EMA 50 | 159.4 | Bullish |
| SMA 100 | 146.1 | Bullish |
| EMA 100 | 149.4 | Bullish |
| SMA 200 | 134.1 | Bullish |
| EMA 200 | 140.5 | Bullish |
Oscillators (daily)
| RSI (14) | 62.55 | Neutral |
| MACD (12, 26) | 4.62 | Bullish |
| Momentum (12) | 0.53 | Bullish |
| Stochastic %K (14) | 68.20 | Neutral |
| Williams %R (14) | -31.80 | Neutral |
| CCI (20) | 93.65 | Neutral |
Pivot points (classic, last session)
S3 165.6 | S2 168.9 | S1 170.9 | Pivot 174.2 | R1 176.2 | R2 179.5 | R3 181.6 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
1.02 USD
Yield on today's price
0.59%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 6 Oct 2026 | 0.2550 |
| 30 Jun 2026 | 0.2550 |
| 31 Mar 2026 | 0.2550 |
| 6 Jan 2026 | 0.2550 |
| 30 Sep 2025 | 0.2480 |
| 1 Jul 2025 | 0.2480 |
| 1 Apr 2025 | 0.2480 |
| 31 Dec 2024 | 0.2480 |
| 1 Oct 2024 | 0.2360 |
| 2 Jul 2024 | 0.2360 |
| 1 Apr 2024 | 0.2360 |
| 29 Dec 2023 | 0.2360 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
A SEC filings
8 Sep 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
1 Sep 2026
10-QSEC EDGAR
Quarterly report
26 Aug 2026
8-KSEC EDGAR
Results of operations
25 Jun 2026
8-KSEC EDGAR
Entered a material agreement
1 Jun 2026
10-QSEC EDGAR
Quarterly report
27 May 2026
8-KSEC EDGAR
Results of operations; Director or officer change
4 May 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
3 Apr 2026
8-KSEC EDGAR
Current report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.